Thr714
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr714  -  BARD1 (human)

Site Information
PKPDSDVtQTINtVA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 465470

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 2 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 1 ) , mutation of modification site ( 2 ) , phospho-antibody ( 2 )
Relevant cell line - cell type - tissue:
Jurkat (T lymphocyte) ( 1 ) , U2OS (bone cell) [GR (human)] ( 2 )

Upstream Regulation
Treatments:
ionizing_radiation ( 2 ) , UV ( 2 )

Downstream Regulation
Effects of modification on biological processes:
RNA stability, altered ( 2 )

References 

1

Possemato A (2007) CST Curation Set: 2927; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

2

Kim HS, et al. (2006) DNA damage-induced BARD1 phosphorylation is critical for the inhibition of messenger RNA processing by BRCA1/BARD1 complex. Cancer Res 66, 4561-5
16651405   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.